Here's Why Omeros Stock Is Tanking Today
Shares of Omeros (NASDAQ: OMER), a biopharmaceutical company, are falling today after the company made a disclosure regarding narsoplimab, an experimental treatment to address side effects of stem cell transplants. Shares of the biotech were down 43.7% as of 11:25 a.m. EDT on Friday.
Omeros has just one revenue stream at the moment, Omidria, an expensive eye-drop solution that gets added to the bill when Medicare patients go under the knife for lens replacements and cataract removals. Omidria is convenient but hardly necessary for these procedures.
That's why investors are eager to see the company launch narsoplimab, an experimental treatment for thrombotic microangiopathy caused by hematopoietic stem cell transplants, or HSCT-TMA. The Food and Drug Administration has been reviewing an application from Omeros since January and was expected to issue a decision later this month.
Source Fool.com
